Georgia is currently home to 1939 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder
NCT05517304
Recruiting
This study effects the effects of transcutaneous cervical vagal nerve stimulation (tcVNS) or a sham control on brain, physiology, and PTSD symptoms in Veterans with posttraumatic stress disorder (PTSD). Veterans undergo brain imaging and physiological measures in conjunction with traumatic scripts before and after three months of twice daily treatment with tcVNS or sham stimulation at home.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2025
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
NCT02305654
Recruiting
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provi... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Grady Health System, Atlanta, Georgia
Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Register for Updates
Monitoring and Outreach for Maternal Safety Postpartum
NCT06899737
Recruiting
Two arm study, intervention and control, to explore the impact of an online training program to help community health workers (CHWs) conduct effective outreach to support postpartum mothers, particularly those at higher risk for complications.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: KDH Research & Communication, Atlanta, Georgia
Conditions: Postpartum, Women, Community Health Workers, Knowledge, High-risk, Self Efficacy, Intention, Attitude
Register for Updates
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Gender:
ALL
Ages:
Between 3 years and 10 years
Trial Updated:
03/26/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Achondroplasia
Register for Updates
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)
NCT06625398
Recruiting
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Agile Clinical Research Trials, LLC, Atlanta, Georgia
Conditions: Thyroid Eye Disease
Register for Updates
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480
Recruiting
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/26/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Microcystic Lymphatic Malformation
Register for Updates
Biomarkers of Reaction To HIIT Exercise
NCT06059872
Recruiting
Stroke survivors with lower limb disability can improve their walking speed with high-intensity interval training (HIIT) rehabilitation therapy. However, some individuals may not respond to HIIT even when fully adherent to the program. To address this, the investigators propose to build a predictive model that identifies if a Veteran with chronic subcortical stroke will improve their walking speed with HIIT by incorporating blood lactate as an early predictor of exercise response, and inhibitory... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/26/2025
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: Stroke, Stroke Rehabilitation, Lower Extremity Weakness, Spastic, Walking, Difficulty
Register for Updates
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT05964413
Recruiting
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Advanced Medical Research, PC, Sandy Springs, Georgia
Conditions: Pyoderma Gangrenosum
Register for Updates
A Retrospective Assessment of OviTex PRS (OviTex)
NCT05736848
Recruiting
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Y Plastic Surgery, Alpharetta, Georgia
Conditions: Reconstructive Surgical Procedures
Register for Updates
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
NCT05640843
Recruiting
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Emory University (Data Collection Only), Atlanta, Georgia
Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Register for Updates
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
NCT05493566
Recruiting
This early phase 1 trial will investigate the combination of low-dose interleukin-2 (IL-2) and pembrolizumab in patients with previously untreated stage IV non-small cell lung cancer (NSCLC). Preclinical data demonstrate reinvigoration of exhausted T cells into an effector-like phenotype with improved anti-tumor activity in response to this combination. This study will evaluate T cell function as well as clinical outcomes associated with this combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Emory University/Winship Cancer Institute, Atlanta, Georgia
Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04647227
Recruiting
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/26/2025
Locations: Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Adult Division, Atlanta, Georgia
Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Register for Updates